欧洲多中心研究:双层血流导向支架治疗宽颈颅内动脉瘤的评估——欧洲血流重定向腔内装置研究
该欧洲注册研究回顾性分析了15个神经血管中心2012年2月至2015年3月连续收治的531例患者579个颅内动脉瘤,采用FRED血流导向装置治疗。结果显示动脉瘤完全闭塞率随时间进展,90天为20%、180天为82.5%、1年为91.3%、超过1年为95.3%;操作相关暂时性和永久性并发症分别为3.2%和0.8%,总死亡率为1.5%。作者认为FRED在真实世界患者中治疗颅内动脉瘤安全有效,多数病例单枚FRED即可在1年时实现完全血管造影闭塞。
要点
- FRED治疗后动脉瘤完全闭塞率随时间递增:90天20%、180天82.5%、1年91.3%、>1年95.3%。
- 操作相关暂时性并发症3.2%、永久性并发症0.8%,总死亡率1.5%。
- 多数病例单枚FRED即可在1年时实现完全血管造影闭塞。
核心结论
- 这项真实世界患者的回顾性研究显示,FRED治疗颅内动脉瘤安全有效,多数病例单枚FRED即可在1年时实现完全血管造影闭塞。
研究设计与样本
- 欧洲注册研究,回顾性分析15个神经血管中心2012年2月至2015年3月连续收治的531例患者579个颅内动脉瘤,均采用FRED治疗。
诊断标准与关键数值
- 7%患者在动脉瘤破裂急性期(≤3天)接受治疗。
- 动脉瘤中位大小7.6 mm(范围1-36.6 mm),中位瘤颈4.5 mm(范围1-30 mm)。
- 516个(89.1%)动脉瘤有>3个月的血管造影随访。
- 完全闭塞率:随访至90±14天为20%(18个),180±20天为82.5%(141个),1年±24天为91.3%(116个),>1年为95.3%(122个)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Endoluminal reconstruction with flow-diverting stents represents a widely accepted technique for the treatment of complex intracranial aneurysms. This European registry study analyzed the initial experience of 15 neurovascular centers with the Flow-Redirection Intraluminal Device (FRED) system.
MATERIALS AND METHODS: Consecutive patients with intracranial aneurysms treated with the FRED between February 2012 and March 2015 were retrospectively reviewed. Complications and adverse events, transient and permanent morbidity, mortality, and occlusion rates were evaluated.
RESULTS: During the defined study period, 579 aneurysms in 531 patients (median age, 54 years; range, 13-86 years) were treated with the FRED. Seven percent of patients were treated in the acute phase (≤3 days) of aneurysm rupture. The median aneurysm size was 7.6 mm (range, 1-36.6 mm), and the median neck size 4.5 mm (range, 1-30 mm). Angiographic follow-up of >3 months was available for 516 (89.1%) aneurysms. There was progressive occlusion witnessed with time, with complete occlusion in 18 (20%) aneurysms followed for up to 90 ± 14 days, 141 (82.5%) for 180 ± 20 days, 116 (91.3%) for 1 year ± 24 days, and 122 (95.3%) aneurysms followed for >1 year. Transient and permanent morbidity occurred in 3.2% and 0.8% of procedures, respectively. The overall mortality rate was 1.5%.
CONCLUSIONS: This retrospective study in real-world patients demonstrated the safety and efficacy of the FRED for the treatment of intracranial aneurysms. In most cases, treatment with a single FRED resulted in complete angiographic occlusion at 1 year.
引用
- Killer-Oberpfalzer M, Kocer N, Griessenauer CJ, et al. European Multicenter Study for the Evaluation of a Dual-Layer Flow-Diverting Stent for Treatment of Wide-Neck Intracranial Aneurysms: The European Flow-Redirection Intraluminal Device Study. AJNR Am J Neuroradiol. 2018. PMID: 29545252. doi:10.3174/ajnr.A5592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。